This is a working overview of freeze-thaw cycle, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-17. Anything still debated is marked as such rather than presented as settled.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
=== Proteins === Arginine's side chain is amphipathic, because at physiological pH it contains a positively charged guanidinium group, which is highly polar, at the end of a hydrophobic aliphatic hydrocarbon chain. Because globular proteins have hydrophobic interiors and hydrophilic surfaces, arginine is typically found on the outside of the protein, where the hydrophilic head group can interact with the polar environment, for example taking part in hydrogen bonding and salt bridges. For this reason, it is frequently found at the interface between two proteins. The aliphatic part of the side chain sometimes remains below the surface of the protein. Arginine residues in proteins can be deiminated by PAD enzymes to form citrulline, in a post-translational modification process called citrullination. This is important in fetal development, is part of the normal immune process, as well as the control of gene expression, but is also significant in autoimmune diseases. Another post-translational modification of arginine involves methylation by protein methyltransferases.
Ojos Locos (pronounced [ˈo.xos ˈlo.kos], Spanish for "Crazy Eyes") was founded in 2010 by restaurateurs Randy DeWitt, Jack Gibbons, Rich Hicks, and Todd East. DeWitt, the owner of parent company Front Burner Restaurants, had previously founded Twin Peaks, a chain of wilderness lodge-themed breastaurants, in 2005. The 2010 opening of the first Ojos Locos restaurant in Dallas coincided closely with the 2010 FIFA World Cup and the chain has consistently emphasized soccer as a principal sport to watch at its locations. Ojos Locos has been called a "Mexican Hooters" or "Twin Peaks for a Hispanic customer base" and markets itself to working class Hispanic men. Workers at the chain frequently speak both Spanish and English and The New York Times has singled out the restaurant as an example of an establishment that has thrived even during an anti-Spanish-language political environment. D Magazine cited it as being the best sports bar in Dallas in 2013. The servers at Ojos Locos are known as "chicas" and wear short skirts along with cleavage and midriff-baring outfits, leading the chain to colloquially be referred to as a "breastaurant". The food served is a mix of Mexican and Southwestern American food developed by chef John Franke, with tacos being a particular specialty. They are also known for their tall beer pitchers called "balones" that contain 100 US fluid ounces (3.0 L). As of 2020, there were thirteen locations across Texas, Arizona, and New Mexico.
Rotary evaporation for high boiling hydrogen bond-forming solvents such as water is often a last recourse, as other evaporation methods or freeze-drying (lyophilization) are available. This is partly due to the fact that in such solvents, the tendency to "bump" is accentuated. The modern centrifugal evaporation technologies are particularly useful when one has many samples to do in parallel, as in medium- to high-throughput synthesis now expanding in industry and academia. Evaporation under vacuum can also, in principle, be performed using standard organic distillation glassware — i.e., without rotation of the sample. The key advantages in use of a rotary evaporator are
==== 2025 ==== UPF1 was found to decline significantly during cellular senescence. The findings suggest that the fall in UPF1 accelerates senescence by slowing down nonsense-mediated mRNA decay. The study was conducted by scientists at Chungnam National University, the Korea Research Institute of Bioscience and Biotechnology, the Korea Advanced Institute of Science and Technology, and the US National Institute on Aging. Scientists at the University of California, Berkeley managed to extend the lifespans of elderly male mice by 73% with a 14% increase in overall lifespan with the Alk5 inhibitor OT+A5i. Researchers at RWTH Aachen University discovered that four senolytic compounds – JQ1, RG7112, nutlin-3a, and AMG232 – can decrease epigenetic age in in vitro blood samples. Researchers at the University of Osaka discovered that the protein AP2A1 may regulate cellular senescence, finding that suppressing the protein in older cells reversed senescence and promoted rejuvenation, whereas overexpression of the protein in young cells advanced senescence. A study by scientists at University College London, Stanford University, Inserm, and the University of Helsinki found that accelerated aging in specific organs could be predictors for diseases across the entire body, not just those affecting that particular organ. A study at the University of Texas at Austin identified the exposure of osteocytes to senescent cells as a key driver of aging in bones.
The pharmacokinetic properties of sitagliptin and vildagliptin appear unaffected by age, sex or BMI. Clinical researches have shown that sitagliptin and vildagliptin do not have the side effects that tend to follow type 2 diabetes treatment, e.g. weight gain and hyperglycemia, but however, other side effects have been observed, including upper respiratory tract infections, sore throat and diarrhea.
Sources: en.wikipedia.org
== Nomenclature == Hemolysis is sometimes called hematolysis, erythrolysis, or erythrocytolysis. The words hemolysis () and hematolysis () both use combining forms conveying the idea of "lysis of blood" (hemo- or hemato- + -lysis). The words erythrolysis () and erythrocytolysis () both use combining forms conveying the idea of "lysis of erythrocytes" (erythro- ± cyto- + -lysis). Red blood cells (erythrocytes) have a short lifespan (approximately 120 days), and old (senescent) cells are constantly removed and replaced with new ones via erythropoiesis. This breakdown/replacement process is called erythrocyte turnover. In this sense, erythrolysis or hemolysis is a normal process that happens continually. However, these terms are usually used to indicate that the lysis is pathological.
== Development == Episode Two was the second in a planned trilogy of shorter episodic games that would continue the story of Half-Life 2 (2004). It was developed simultaneously with Episode One (2006) by a team led by David Speyrer. This schedule of simultaneous development aided them in streamlining the story between the two games to create an immersive story. The technology used was the same for both games, allowing the development teams to quickly fix any technical problems that might arise from either game; this happened often because of the multi-platform release. The team originally planned the ending to feature a comical sequence with Lamarr, Kleiner's pet headcrab, floating in space outside the rocket Gordon launches into space; however, Valve president Gabe Newell requested killing off a major character to create a cliffhanger for Episode Three. On July 13, 2006, Valve announced that Episode Two would be released on Xbox 360 and PlayStation 3 in addition to Windows. Valve handled the development for the PC and Xbox 360, while Electronic Arts (EA) worked on the PlayStation 3 version. It was announced on September 7, 2007, that the PlayStation 3 version would be delayed because the EA studio behind the game was in the United Kingdom, away from Valve's development team, and therefore lagged behind in its schedule. According to Valve's marketing director, Doug Lombardi, the Xbox 360, PlayStation 3 and Windows versions would be identical in functionality and performance. An audio commentary is also featured, as in Episode One and Lost Coast.
Soon after plants are water-stressed and the roots are deficient in water, a signal moves up to the leaves, causing the formation of ABA precursors there, which then move to the roots. The roots then release ABA, which is translocated to the foliage through the vascular system and modulates potassium and sodium uptake within the guard cells, which then lose turgidity, closing the stomata.
=== Section Cyclopia === Cyclopia alpina A.L. Schutte Cyclopia falcata (Harv.) Kies (= Cyclopia subternata Vogel) Cyclopia galioides (Bergius) DC. Cyclopia genistoides (L.) Vent. Cyclopia intermedia E. Mey.
=== Acute pain === The beak is a complex, functional organ with an extensive nervous supply including nociceptors that sense pain and noxious stimuli. These would almost certainly be stimulated during beak trimming, indicating strongly that acute pain would be experienced. Behavioural evidence of pain after beak trimming in layer hen chicks has been based on the observed reduction in pecking behavior, reduced activity and social behavior, and increased sleep duration. In Japanese quail, beak-trimming by cauterization caused lower body weights and feed intake in the period just after beak trimming. Beak trimmed Muscovy ducks spent less time engaging in beak-related behaviours (preening, feeding, drinking, exploratory pecking) and more time resting than non-trimmed ducks in the days immediately post-trim. These differences disappeared by 1 week post-trim. At 1 week post-trim the trimmed ducks weighed less than non-trimmed ducks, but this difference disappeared by 2 weeks post-trim. It is, however, unclear if the above changes in behaviour arise from pain or from a loss of sensitivity in the beak. Pecking force has been found to decrease after beak trimming in adult hens, possibly indicating that hens are protecting a painful area from further stimulation. However, pecking force did not differ between chicks with or without minor beak-trims at 2 to 9 days of age, suggesting that chicks with minor beak-trims do not experience pain from the beak.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.